GSK to acquire three lung cancer drug candidates

Created at 9 Jun · 6:33 AM1 source↑ Market-relevant

IN SHORT

GSK is set to acquire three drug candidates for lung cancer, with two of them currently under review by the FDA for approval this year. The acquisition will give GSK full ownership of these potential treatments.

Key Numbers

3lung cancer drug candidates to be acquired

2drug candidates awaiting FDA approval this year

Who's Involved

GSK

pharmaceutical company acquiring lung cancer drug candidates

FDA

U.S. Food and Drug Administration reviewing drug candidates

↳ Why This Matters

This acquisition strengthens GSK's oncology pipeline, potentially offering new treatment options for lung cancer patients and enhancing the company's market position in a key therapeutic area.

Key facts

GSK is acquiring three drug candidates for lung cancer.
Two of the drug candidates are currently under FDA review for approval this year.
The acquisition will grant GSK full ownership of these potential treatments.

GSK is set to acquire three drug candidates for lung cancer, with two of them currently under review by the FDA for approval this year. The acquisition will grant GSK full ownership of these potential treatments.

The two drug candidates currently under FDA review are expected to receive a decision on their approval status within the year, marking a significant step in GSK's expansion within the oncology sector.

FREQUENTLY ASKED

GSK is acquiring three drug candidates for lung cancer.

Two of the three drug candidates are currently awaiting FDA approval this year.

The acquisition will give GSK full ownership of these potential treatments, strengthening its oncology pipeline.

What Happens Next

01FDA decision on the two lung cancer drug candidates' approval.

GSK to acquire three lung cancer drug candidates

PiQ Daily

Key facts

GSK to acquire three lung cancer drug candidates

PiQ Daily

Key facts

Get the newsletter.